Indian drugmaker Glenmark Pharmaceuticals Ltd. announced its partner Forest Laboratories gained FDA approval to carry a Phase II trial in the U.S. for its drug candidate GRC 3886, a PDE4 inhibitor molecule that treats chronic obstructive pulmonary disorder. The agency granted the clearance after Forest Laboratories addressed nonclinical questions concerning the drug.

Related Summaries